China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light

Strong Overseas Efficacy Data

Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.

CHINA PUBLIC HEALTH FIGURE ZHONG NANSHAN (FOURTH FORM LEFT) LEADS BRII PHASE II STUDY IN CHINA • Source: Scrip

More from China

More from Focus On Asia